Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?

作者:Bouattour Mohamed*; Rousseau Benoit; Wassermann Johanna; Payance Audrey; Huillard Olivier
来源:Journal of Clinical Oncology, 2015, 33(22): 2484-U107.
DOI:10.1200/JCO.2014.60.6954